Clinical Trial Update: Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating whether budesonide reduces the incidence of grade 2 or higher diarrhea in multiple myeloma patients undergoing autologous stem…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Leukemia

Drugs mentioned

• Budesonide (BUDESONIDE)

Snippet

Sponsor: University of Utah | Conditions: Multiple Myeloma, Plasma Cell Leukemia | Phase 2 | Status: RECRUITING